Research programme: bifunctional fusion proteins - Kadmon Corporation

Drug Profile

Research programme: bifunctional fusion proteins - Kadmon Corporation

Alternative Names: Bi-functional anti-PD-L1/IL-15 fusion protein - Kadmon Corporation; KD-033

Latest Information Update: 08 May 2016

Price : $50

At a glance

  • Originator Kadmon Corporation
  • Class Immunoglobulin fusion proteins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action CD274 antigen inhibitors; Immunostimulants; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Apr 2016 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 03 Nov 2015 Pharmacodynamics and toxicity data from a preclinical trial in Cancer released by Kadmon
  • 19 Nov 2014 Preclinical pharmacodynamics and safety data in Cancer presented at the 26th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top